BioSource to Acquire San Francisco Company

BioSource Industries Inc., a Camarillo supplier of antibodies and other products to the medical and scientific research market, has signed a letter of intent to acquire a San Francisco firm, Tago Inc. The deal, for stock valued at $4 million, will more than double BioSource’s products and will give the company a NASDAQ trading symbol.

Upon completion of the merger, BioSource will change its name to BioSource International Inc. and will be delisted from the Vancouver Stock Exchange, said Benjamin Matzilevich, vice president for marketing.

“The deal is a bit complicated,” he said. “Technically, Tago is the acquiring company. That will enable us to be traded under their NASDAQ symbol, TAGO.” The symbol may be changed later, the company said.

BioSource’s president and chief executive, James H. Chamberlain, will head the combined companies, Matzilevich said.

Matzilevich said BioSource manufactures 250 products and Tago markets 350 items for basic scientific research. BioSource specializes in reagents, which detect, measure and transform various substances.

BioSource International will have 44 employees and $5 million in annual sales, Matzilevich added. He said the company expects to expand both its revenues and work force.